Valneva completes enrollment for adolescent phase 3 trial of single-shot chikungunya vaccine candidate

Saint - herblain ( france), february 14 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that it completed enrollment and vaccination for a phase 3 trial in adolescents, vla1553-321, of its single-shot chikungunya vaccine candidate, vla1553. first results of the trial are expected mid-2023.
VALN Ratings Summary
VALN Quant Ranking